Latest Period
Q4 2025
Security Snapshot
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) Institutional Ownership
CUSIP: 53566P109
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
121
Shares (Excl. Options)
101,657,149
Price
$1.67
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common shares
- Symbol
- LCTX on NYSE
- Shares outstanding
- 250,425,788
- Price per share
- $1.49
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 101,657,149
- Total reported value
- $169,765,856
- % of total 13F portfolios
- 0%
- Share change
- +13,586,190
- Value change
- +$22,647,526
- Number of holders
- 121
- Price from insider filings
- $1.49
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- LCTX - Lineage Cell Therapeutics, Inc. - Common shares is tracked under CUSIP 53566P109.
- 121 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 121 to 69 between Q4 2025 and Q1 2026.
- Reported value moved from $169,765,856 to $48,352,407.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 121 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 53566P109?
CUSIP 53566P109 identifies LCTX - Lineage Cell Therapeutics, Inc. - Common shares in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 53566P109:
Significant Owners of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 23% | -5.6% | $97,763,723 | 57,848,357 | 0% | NEAL C. BRADSHER | 12 Nov 2025 | |
| Chernett Jorey | 5% | $13,848,454 | 11,445,003 | Chernett Jorey | 22 Sep 2025 | |||
| BlackRock, Inc. | 1% | -80% | $2,027,626 | -$8,365,103 | 2,234,545 | -80% | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Dec 2025, 121 institutional investors reported holding 101,657,149 shares of Lineage Cell Therapeutics, Inc. - Common shares (LCTX). This represents 41% of the company’s total 250,425,788 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) together control 39% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BROADWOOD CAPITAL INC | 20% | 49,560,992 | 0% | 5% | $82,766,857 |
| VANGUARD GROUP INC | 3.9% | 9,644,276 | +7.1% | 0% | $16,105,941 |
| Defender Capital, LLC. | 2.7% | 6,829,099 | 3.7% | $11,405,031 | |
| RAFFLES ASSOCIATES LP | 2.1% | 5,362,788 | -0.46% | 6.7% | $8,955,856 |
| COMERICA BANK | 1.8% | 4,600,000 | 0% | 0.03% | $7,682,000 |
| BlackRock, Inc. | 1.5% | 3,834,113 | +72% | 0% | $6,402,969 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.98% | 2,461,193 | +1.7% | 0% | $4,112,193 |
| RENAISSANCE TECHNOLOGIES LLC | 0.96% | 2,404,800 | +26% | 0.01% | $4,016,016 |
| MILLENNIUM MANAGEMENT LLC | 0.84% | 2,110,419 | -21% | 0% | $3,524,400 |
| MORGAN STANLEY | 0.8% | 1,998,663 | +99% | 0% | $3,337,767 |
| GOLDMAN SACHS GROUP INC | 0.57% | 1,438,746 | +894% | 0% | $2,402,706 |
| MARSHALL WACE, LLP | 0.54% | 1,362,061 | 0% | $2,274,642 | |
| STATE STREET CORP | 0.41% | 1,016,211 | +6.3% | 0% | $1,697,072 |
| JANE STREET GROUP, LLC | 0.4% | 1,004,794 | +594% | 0% | $1,678,007 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.28% | 706,415 | +282% | 0% | $1,179,713 |
| RED CRANE WEALTH MANAGEMENT, LLC | 0.24% | 597,263 | +17% | 0.82% | $997,429 |
| CITADEL ADVISORS LLC | 0.2% | 507,052 | +161% | 0% | $846,777 |
| NORTHERN TRUST CORP | 0.19% | 479,273 | +8.1% | 0% | $800,386 |
| Informed Momentum Co LLC | 0.18% | 442,221 | 0% | 0.08% | $738,509 |
| BARCLAYS PLC | 0.14% | 348,510 | +34850900% | 0% | $582,012 |
| GSA CAPITAL PARTNERS LLP | 0.13% | 330,981 | -51% | 0.05% | $553,000 |
| OMERS ADMINISTRATION Corp | 0.11% | 283,200 | 0% | $472,944 | |
| SEI INVESTMENTS CO | 0.11% | 269,311 | 0% | $449,749 | |
| TWO SIGMA INVESTMENTS, LP | 0.11% | 265,585 | -25% | 0% | $443,527 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.09% | 221,000 | 0% | 0.01% | $369,070 |
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 30,603,928 | $48,352,407 | +$9,183,585 | $1.58 | 69 |
| 2025 Q4 | 101,657,149 | $169,765,856 | +$22,647,526 | $1.67 | 121 |
| 2025 Q3 | 87,923,479 | $148,572,802 | -$9,340,067 | $1.69 | 111 |
| 2025 Q2 | 97,785,816 | $88,366,897 | -$8,826,258 | $0.91 | 128 |
| 2025 Q1 | 109,349,495 | $49,687,946 | +$369,638 | $0.45 | 126 |
| 2024 Q4 | 107,111,044 | $53,827,848 | +$3,921,589 | $0.50 | 119 |
| 2024 Q3 | 94,568,251 | $85,611,699 | -$260,148 | $0.91 | 112 |
| 2024 Q2 | 94,431,242 | $94,175,668 | +$447,460 | $1.00 | 110 |
| 2024 Q1 | 93,427,423 | $138,270,047 | +$26,536,201 | $1.48 | 113 |
| 2023 Q4 | 75,708,353 | $82,523,932 | +$188,614 | $1.09 | 114 |
| 2023 Q3 | 75,504,077 | $89,104,877 | -$402,119 | $1.18 | 102 |
| 2023 Q2 | 75,637,865 | $106,648,039 | +$8,457,693 | $1.41 | 105 |
| 2023 Q1 | 69,793,059 | $104,687,354 | +$7,197,215 | $1.50 | 114 |
| 2022 Q4 | 65,070,787 | $76,138,155 | +$591,571 | $1.17 | 99 |
| 2022 Q3 | 64,712,443 | $73,129,667 | -$348,315 | $1.13 | 88 |
| 2022 Q2 | 64,980,785 | $102,682,821 | -$12,116,491 | $1.58 | 84 |
| 2022 Q1 | 72,831,378 | $112,314,619 | -$3,915,128 | $1.54 | 99 |
| 2021 Q4 | 73,975,180 | $181,237,026 | -$5,349,258 | $2.45 | 110 |
| 2021 Q3 | 75,827,690 | $191,741,083 | +$6,640,880 | $2.52 | 106 |
| 2021 Q2 | 73,147,470 | $208,518,897 | +$38,013,987 | $2.85 | 103 |
| 2021 Q1 | 60,314,515 | $141,778,049 | +$12,436,479 | $2.35 | 90 |
| 2020 Q4 | 55,072,841 | $96,924,151 | +$3,142,777 | $1.76 | 78 |
| 2020 Q3 | 53,561,495 | $50,165,088 | -$1,850,541 | $0.94 | 65 |
| 2020 Q2 | 55,701,303 | $48,461,276 | -$6,974,131 | $0.87 | 80 |
| 2020 Q1 | 63,835,650 | $52,851,654 | +$405,531 | $0.83 | 81 |
| 2019 Q4 | 63,343,880 | $56,369,746 | -$1,146,000 | $0.89 | 86 |
| 2019 Q3 | 64,455,811 | $63,153,426 | +$63,033,394 | $0.98 | 81 |
| 2019 Q2 | 17,974 | $20,000 | +$20,000 | $1.11 | 1 |